Session Title: Evolving Landscape of IgA Nephropathy in 2026 and Beyond
Organized by: Chugai Pharmaceutical Co.,Ltd.
Session Description:
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, and carries a significant lifetime risk of kidney failure as well as an enormous socioeconomic burden. Previous clinical studies of IgAN largely focused on optimizing supportive care, blood pressure control and lifestyle modifications. Various corticosteroid therapies have shown effectiveness, but have considerably increased the risk of serious adverse events. Recent research advances have provided insights into the pathogenesis of IgAN. An increase in circulating galactose-deficient IgA1, derived from the mucosal immune system, generates immune complexes with IgG and IgA that deposit within the glomeruli, which triggers inflammation, complement activation and kidney damage. This understanding of the pathogenesis of IgAN led to an explosion of clinical drug development in this disease. In the KDIGO guideline 2025, the focus of management is to simultaneously prevent or reduce IgA-containing immune complex formation and manage the consequences of existing IgAN-induced nephron loss. In recent years, various novel therapies have been approved, and selective or combined APRIL and/or BAFF antagonists, and complement inhibitors are in the late States of clinical development. Current status of IgAN treatment and future strategies to improve outcomes for patients with IgAN will be discussed in this symposium.
Learning Objectives:
• Describe the pathogenesis of IgA nephropathy.
• Describe current management strategies based on KDIGO 2025 guidelines for preventing immune complex formation and managing nephron loss.
• Describe emerging therapies including approved novel agents for IgA nephropathy.
| Time | Session |
|---|---|
|
5 p.m.
6 p.m.
|